Eishita Pal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eishita Pal has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Jean Christophe Rusatira
Affiliation Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America
4 shared publications Ayesha Khan
Affiliation Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America
2 shared publicationsCharles Preston
Affiliation Gates Foundation, Seattle, Washington, United States of America
2 shared publications- Henry Joseph Michtalik
Department of Health Policy and Management, Johns Hopkins School of Hygiene and Public Health, Baltimore, Maryland, USA
2 shared publications Henry Michtalik
Affiliation Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America
2 shared publications- Jean Berchmans Uwimana
Affiliation Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America
2 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 6 (9) , e0006326
Nearly one in five essential medicines fail quality standards in Africa: A systematic review and meta-analysis of MNCH medicines and antimalarials
Substandard and falsified (SF) medicines pose a major threat to maternal, newborn, and child health (MNCH) and malaria control in Africa, yet their true burden remains uncertain. We conducted a systematic review and meta-analysis of studies published between 2010 and 2025 that chemically tested the quality of essential MNCH and antimalarial medicines collected in African countries. Following PRISMA 2020 guidelines and a registered PROSPERO protocol, we searched PubMed, Embase, Web of Science, and WHO databases, screened 3,178 records, and included 123 studies from 34 countries reporting on 36,069 medicine samples. Studies were appraised with the MEDQUARG checklist, and random-effects meta-analyses with Freeman–Tukey transformation were used to estimate pooled SF prevalence overall and by therapeutic class, country, and subregion. Meta-regression explored study-level drivers of heterogeneity. Overall, 17.9% (95% CI 13.6–22.7) of tested medicines failed quality standards. Failure rates were highest for corticosteroids (65.0%), uterotonics (43.9%), and hematinics (34.7%); antimalarials, antihypertensives, and antibiotics ranged from 15-20%. Estimates for corticosteroids and hematinics carried wide confidence intervals, reflecting sparse underlying data. Western and Central Africa had the greatest regional burdens, whereas Southern Africa showed lower pooled estimates but with sparse data. Substandard medicines accounted for most poor-quality products (pooled prevalence 12.8%), while falsified medicines were less common (1.2%). Therapeutic category, geographic subregion, and use of mystery-client purchasing were significant predictors of heterogeneity, whereas publication year and methodological quality were not. Nearly one in five essential MNCH and antimalarial medicines tested in Africa are SF, posing a major barrier to reducing preventable maternal, neonatal, and child mortality. Strengthened regulatory systems, risk-based post-market surveillance, and priority attention to high-risk therapeutics, particularly uterotonics and antimalarials, are urgently needed. As the African Medicines Agency becomes operational, this evidence base offers a concrete foundation for directing continental regulatory investment where it is most needed.
- 2 September 2026
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 6 (9) , e0006326
Open AccessNearly one in five essential medicines fail quality standards in Africa: A systematic review and meta-analysis of MNCH medicines and antimalarials
Substandard and falsified (SF) medicines pose a major threat to maternal, newborn, and child health (MNCH) and malaria control in Africa, yet their true burden remains uncertain. We conducted a systematic review and meta-analysis of studies published between 2010 and 2025 that chemically tested the quality of essential MNCH and antimalarial medicines collected in African countries. Following PRISMA 2020 guidelines and a registered PROSPERO protocol, we searched PubMed, Embase, Web of Science, and WHO databases, screened 3,178 records, and included 123 studies from 34 countries reporting on 36,069 medicine samples. Studies were appraised with the MEDQUARG checklist, and random-effects meta-analyses with Freeman–Tukey transformation were used to estimate pooled SF prevalence overall and by therapeutic class, country, and subregion. Meta-regression explored study-level drivers of heterogeneity. Overall, 17.9% (95% CI 13.6–22.7) of tested medicines failed quality standards. Failure rates were highest for corticosteroids (65.0%), uterotonics (43.9%), and hematinics (34.7%); antimalarials, antihypertensives, and antibiotics ranged from 15-20%. Estimates for corticosteroids and hematinics carried wide confidence intervals, reflecting sparse underlying data. Western and Central Africa had the greatest regional burdens, whereas Southern Africa showed lower pooled estimates but with sparse data. Substandard medicines accounted for most poor-quality products (pooled prevalence 12.8%), while falsified medicines were less common (1.2%). Therapeutic category, geographic subregion, and use of mystery-client purchasing were significant predictors of heterogeneity, whereas publication year and methodological quality were not. Nearly one in five essential MNCH and antimalarial medicines tested in Africa are SF, posing a major barrier to reducing preventable maternal, neonatal, and child mortality. Strengthened regulatory systems, risk-based post-market surveillance, and priority attention to high-risk therapeutics, particularly uterotonics and antimalarials, are urgently needed. As the African Medicines Agency becomes operational, this evidence base offers a concrete foundation for directing continental regulatory investment where it is most needed.
- Open Access
- 3 June 2026
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 6 (6) , e0006576
Tiered manufacturing of pharmaceuticals as a commercial determinant of health: Implications for medicine quality and equity
Tiered manufacturing, the practice of adapting different levels of pharmaceutical production standards to low- and middle-income countries (LMICs) versus high-income countries, has not been investigated as a commercial determinant of health (CDoH), defined by the World Health Organization as a private sector activity affecting public health. This paper examines this practice and its implications for medicine quality, universal health coverage, and global health equity. Guided by the CDoH framework, we conducted semi-structured interviews with 31 mostly India-based experts in pharmaceutical development, manufacturing, procurement, and regulation between May and July 2025. Purposive sampling ensured variation in geography, organizational type, and role. Transcripts were coded deductively using CDoH domains and inductively for emergent themes. Respondents consistently described “tiered manufacturing” — using different production standards by market. Medicines for countries regulated by Stringent Regulatory Authorities (SRA) (now called WHO Listed Authorities (WLA)) adhere to international good manufacturing practices (GMP) through rigorous documentation, stability testing, impurity profiling, and advanced infrastructure. In contrast, products supplied to LMICs are often produced with uncertain GMP compliance, cheaper raw materials, weaker documentation, and less stringent oversight, leading to variable quality and shortened shelf life. Commercial drivers were key determinants. Proposed solutions include improved mechanisms to verify versions of products being received, reliance on WHO prequalification or WLA approvals, procurement conditionality and strengthened local regulatory and manufacturing capacity. Tiered manufacturing was widely perceived as a common practice among respondents. Recognition of this practice as a CDoH is essential to strengthen regulatory reliance and enforcement, procurement leverage, and sustainable capacity-building, ensuring quality medicines for all globally.
- 3 June 2026
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 6 (6) , e0006576
Open AccessTiered manufacturing of pharmaceuticals as a commercial determinant of health: Implications for medicine quality and equity
Tiered manufacturing, the practice of adapting different levels of pharmaceutical production standards to low- and middle-income countries (LMICs) versus high-income countries, has not been investigated as a commercial determinant of health (CDoH), defined by the World Health Organization as a private sector activity affecting public health. This paper examines this practice and its implications for medicine quality, universal health coverage, and global health equity. Guided by the CDoH framework, we conducted semi-structured interviews with 31 mostly India-based experts in pharmaceutical development, manufacturing, procurement, and regulation between May and July 2025. Purposive sampling ensured variation in geography, organizational type, and role. Transcripts were coded deductively using CDoH domains and inductively for emergent themes. Respondents consistently described “tiered manufacturing” — using different production standards by market. Medicines for countries regulated by Stringent Regulatory Authorities (SRA) (now called WHO Listed Authorities (WLA)) adhere to international good manufacturing practices (GMP) through rigorous documentation, stability testing, impurity profiling, and advanced infrastructure. In contrast, products supplied to LMICs are often produced with uncertain GMP compliance, cheaper raw materials, weaker documentation, and less stringent oversight, leading to variable quality and shortened shelf life. Commercial drivers were key determinants. Proposed solutions include improved mechanisms to verify versions of products being received, reliance on WHO prequalification or WLA approvals, procurement conditionality and strengthened local regulatory and manufacturing capacity. Tiered manufacturing was widely perceived as a common practice among respondents. Recognition of this practice as a CDoH is essential to strengthen regulatory reliance and enforcement, procurement leverage, and sustainable capacity-building, ensuring quality medicines for all globally.
- Open Access
- 16 January 2026
- Published by BMJ in BMJ Connections Oncology
- Vol. 3 (1) , e000069
Healthcare providers’ knowledge gaps and educational needs in addressing substandard and falsified oncology drugs: a scoping review
Introduction: Substandard and falsified (SF) drugs are an increasingly widespread threat to global health. Expensive medicines that are prone to shortages, such as cancer therapies, tend to be a target of counterfeiters due to their high profit potential. There are concerns that healthcare providers (HCPs) lack knowledge of SF drug threats and how to identify and report suspicious drugs. We conducted this scoping review to map evidence on oncology HCPs’ awareness, knowledge and educational needs regarding SF oncology drugs. Specifically, we examined HCPs’ awareness of SF prevalence, confidence in counselling patients to prevent exposure and ability to report suspected cases to regulatory authorities. Research design and methods: This scoping review was conducted using the Arksey and O’Malley scoping review framework. We searched PubMed and Embase databases through 14 December 2024 using keywords on the topics of: (1) SF drugs in oncology, (2) challenges and supply chain integrity specific to oncology drugs and antineoplastics and (3) successful education and training models for HCPs working in oncology. Thematic analysis and narrative synthesis were conducted on the included papers. Results: We identified 50 studies from 22 countries for our thematic analysis. Drug shortages, affordability and the rise of e-pharmacy were found to contribute to the propagation of SF oncology drugs globally. HCP awareness of SF drugs was generally low. Successful drug safety education interventions predominantly focused on pharmacovigilance and adverse drug reaction reporting rather than identifying SF drugs and counselling patients on safe drug purchasing practices. Conclusions: SF oncology drugs are a global public health issue and HCPs generally lack adequate awareness of this problem. Educational interventions should be targeted at improving oncology HCPs’ knowledge of SF drug prevalence, and their ability to both identify and report SF drugs to the proper authorities and counsel patients on how to purchase drugs safely.
- 16 January 2026
- Published by BMJ in BMJ Connections Oncology
- Vol. 3 (1) , e000069
Open AccessHealthcare providers’ knowledge gaps and educational needs in addressing substandard and falsified oncology drugs: a scoping review
Introduction: Substandard and falsified (SF) drugs are an increasingly widespread threat to global health. Expensive medicines that are prone to shortages, such as cancer therapies, tend to be a target of counterfeiters due to their high profit potential. There are concerns that healthcare providers (HCPs) lack knowledge of SF drug threats and how to identify and report suspicious drugs. We conducted this scoping review to map evidence on oncology HCPs’ awareness, knowledge and educational needs regarding SF oncology drugs. Specifically, we examined HCPs’ awareness of SF prevalence, confidence in counselling patients to prevent exposure and ability to report suspected cases to regulatory authorities. Research design and methods: This scoping review was conducted using the Arksey and O’Malley scoping review framework. We searched PubMed and Embase databases through 14 December 2024 using keywords on the topics of: (1) SF drugs in oncology, (2) challenges and supply chain integrity specific to oncology drugs and antineoplastics and (3) successful education and training models for HCPs working in oncology. Thematic analysis and narrative synthesis were conducted on the included papers. Results: We identified 50 studies from 22 countries for our thematic analysis. Drug shortages, affordability and the rise of e-pharmacy were found to contribute to the propagation of SF oncology drugs globally. HCP awareness of SF drugs was generally low. Successful drug safety education interventions predominantly focused on pharmacovigilance and adverse drug reaction reporting rather than identifying SF drugs and counselling patients on safe drug purchasing practices. Conclusions: SF oncology drugs are a global public health issue and HCPs generally lack adequate awareness of this problem. Educational interventions should be targeted at improving oncology HCPs’ knowledge of SF drug prevalence, and their ability to both identify and report SF drugs to the proper authorities and counsel patients on how to purchase drugs safely.
- Open Access
- 12 September 2025
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 18 (1)
Assessing knowledge, attitudes, and practices and demand-side interventions for combating substandard and falsified medicines: a scoping review
The proliferation of substandard and falsified medical products (SFM) poses a significant threat to public health globally. Despite rigorous surveillance and law enforcement efforts, risk of exposure to SFM is on the rise, notably through online pharmacies. The current interventions predominantly target the pharmaceutical supply chains through legal and regulatory frameworks, while there is a noticeable deficiency in focusing on interventions for healthcare providers and consumers. This scoping review aims to summarise the current literature on SFM, focusing on their health and economic consequences, and to assess the knowledge, attitudes, and practices of healthcare providers and the general public. A comprehensive literature search was conducted across PubMed, Embase, and Scopus databases, focusing on studies from the past 15 years that provided estimates on mortality, morbidities and economic impacts of SFM and covered the following topic areas: knowledge, attitudes and practices of healthcare providers, patients and general public; and population level interventions regarding SFM. We exclude non-peer-reviewed literature. A total of 78 studies met the inclusion criteria and were analyzed. These studies suggest that the data on adverse effects on health and economic impact of SF medicines are predominantly based on statistical models, and empirical data are grossly lacking. Knowledge of risks, identification of SFM, and reporting to regulatory authorities are substantially low among healthcare providers and general public. This review highlights the need for innovative, targeted strategies – such as digital health interventions, enhanced training programs for healthcare providers, and context-specific public awareness campaigns – to bridge the gap between awareness and effective practice. Our study underscores that a multifaceted approach must not only reinforce regulatory frameworks and surveillance systems for protecting the supply chains but also proactively empower both health providers and consumers to identify and combat SFM in today’s rapidly evolving digital landscape.
- 12 September 2025
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 18 (1)
Open AccessAssessing knowledge, attitudes, and practices and demand-side interventions for combating substandard and falsified medicines: a scoping review
The proliferation of substandard and falsified medical products (SFM) poses a significant threat to public health globally. Despite rigorous surveillance and law enforcement efforts, risk of exposure to SFM is on the rise, notably through online pharmacies. The current interventions predominantly target the pharmaceutical supply chains through legal and regulatory frameworks, while there is a noticeable deficiency in focusing on interventions for healthcare providers and consumers. This scoping review aims to summarise the current literature on SFM, focusing on their health and economic consequences, and to assess the knowledge, attitudes, and practices of healthcare providers and the general public. A comprehensive literature search was conducted across PubMed, Embase, and Scopus databases, focusing on studies from the past 15 years that provided estimates on mortality, morbidities and economic impacts of SFM and covered the following topic areas: knowledge, attitudes and practices of healthcare providers, patients and general public; and population level interventions regarding SFM. We exclude non-peer-reviewed literature. A total of 78 studies met the inclusion criteria and were analyzed. These studies suggest that the data on adverse effects on health and economic impact of SF medicines are predominantly based on statistical models, and empirical data are grossly lacking. Knowledge of risks, identification of SFM, and reporting to regulatory authorities are substantially low among healthcare providers and general public. This review highlights the need for innovative, targeted strategies – such as digital health interventions, enhanced training programs for healthcare providers, and context-specific public awareness campaigns – to bridge the gap between awareness and effective practice. Our study underscores that a multifaceted approach must not only reinforce regulatory frameworks and surveillance systems for protecting the supply chains but also proactively empower both health providers and consumers to identify and combat SFM in today’s rapidly evolving digital landscape.